Business Context and Reporting Period
This Form 8-K Current Report was filed by Salarius Pharmaceuticals, Inc. (not Decoy Therapeutics Inc.) on July 2, 2021. The registrant is a Delaware corporation with its principal executive offices in Houston, Texas, and its common stock trades on The Nasdaq Capital Market under the symbol SLRX.
Key Financial Metrics and Capital Activities
The filing details an "At the Market" (ATM) equity offering program rather than standard operating financial results.
- New Offering Capacity: The Company filed a prospectus supplement to register the sale of common stock with an aggregate offering price of up to $25,000,000.
- Previous Proceeds: Under the prior prospectus supplement, the Company sold 2,820,493 shares for net proceeds of $6.3 million.
- Agent: Ladenburg Thalmann & Co. Inc. acts as the sales agent.
- Operating Metrics: The filing text does not provide clear values for revenue, profit, cash flow, margins, or debt levels.
Material Changes
The primary material change is the superseding of the prior prospectus supplement with a new one dated July 2, 2021. The Company has ceased offering shares under the previous supplement and will now utilize the new $25 million capacity. If the Company determines to offer more than $25 million in the future, it will be required to file another prospectus supplement.
Outlook, Risks, and Management Commentary
The filing does not contain forward-looking guidance, management commentary on operational outlook, or specific risk factors beyond standard legal disclaimers. It notes that the report does not constitute an offer to sell shares in any jurisdiction where such an offer would be unlawful. A legal opinion regarding the legality of the issuance is filed as Exhibit 5.1.
Investor Verification Checklist
- Verify the correct registrant name is Salarius Pharmaceuticals, Inc. (SLRX), not Decoy Therapeutics Inc.
- Confirm the total remaining capacity under the new $25 million prospectus supplement.
- Review the Company's most recent 10-Q or 10-K for actual revenue, cash flow, and liquidity metrics, as they are absent from this 8-K.
- Monitor future filings for additional prospectus supplements if the $25 million limit is reached.